All Posts

' Looking Back & Forward '' Market landscape   VC and M&A activity have declined in both total deal count and value over the past three years, while partnerships show fewer deals but higher total deal value. This shift represents a significant change in the investment landscape, as members at BROTHERS & Partners have identified the following investment trends:  - Investment trends :  Late-stage deals take the spotlight.  Rare diseases, next-gen modalities, and AI/ ML lead the

Neurodegeneration Melatonin shows promise in Alzheimer's treatment by restoring circadian rhythms and reducing neurodegenerative symptoms, researchers have demonstrated in a groundbreaking study. A groundbreaking study conducted by researchers at Nanjing Pharmaceutical University has introduced an innovative therapeutic strategy for combating Alzheimer's disease , linking aging processes with neurodegenerative diseases. The researchers employed an AI-driven screening method

OrbiMed is a global healthcare investment firm that finances companies across all stages of the life sciences sector, from early-stage biotechs to large pharmaceutical enterprises. How would you describe the current investment climate for the biotech sector? Do you believe the difficult period the industry has faced in recent years is finally coming to an end? I think it’s an exciting time for the sector. It’s never easy to be a biotech investor, but over the last several mon

The geopolitical landscape is the key challenge that they face in their investment decision-making. The CIOs of British and mainland...